Brokerages expect that AbbVie Inc. (NYSE:ABBV) will announce sales of $7.56 billion for the current quarter, according to Zacks. Five analysts have made estimates for AbbVie’s earnings. The lowest sales estimate is $7.51 billion and the highest is $7.63 billion. AbbVie reported sales of $6.80 billion in the same quarter last year, which indicates a positive year over year growth rate of 11.2%. The company is scheduled to report its next quarterly earnings report on Friday, January 26th.

According to Zacks, analysts expect that AbbVie will report full-year sales of $7.56 billion for the current financial year, with estimates ranging from $27.82 billion to $28.11 billion. For the next year, analysts forecast that the business will report sales of $31.35 billion per share, with estimates ranging from $30.77 billion to $32.63 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover AbbVie.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 164.66% and a net margin of 24.38%. The firm had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. During the same period last year, the company earned $1.21 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis.

A number of research firms have recently commented on ABBV. SunTrust Banks, Inc. reaffirmed a “buy” rating on shares of AbbVie in a report on Monday, October 30th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $85.00 price target on shares of AbbVie in a report on Thursday, August 3rd. Barclays PLC reaffirmed a “hold” rating and issued a $68.00 price target on shares of AbbVie in a report on Thursday, September 28th. Evercore ISI reaffirmed an “outperform” rating and issued a $100.00 price target (up from $95.00) on shares of AbbVie in a report on Saturday, September 30th. Finally, Leerink Swann lowered their price objective on AbbVie from $108.00 to $107.00 and set an “outperform” rating on the stock in a research report on Monday, October 30th. Eight analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $93.68.

AbbVie (NYSE:ABBV) opened at $92.96 on Tuesday. AbbVie has a twelve month low of $55.87 and a twelve month high of $98.26. The company has a debt-to-equity ratio of 5.63, a current ratio of 1.38 and a quick ratio of 1.25. The company has a market capitalization of $148,190.00, a price-to-earnings ratio of 17.38, a PEG ratio of 1.28 and a beta of 1.52.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a dividend of $0.71 per share. This is an increase from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date is Thursday, January 11th. This represents a $2.84 dividend on an annualized basis and a yield of 3.06%. AbbVie’s dividend payout ratio (DPR) is presently 61.84%.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/07/analysts-expect-abbvie-inc-abbv-will-post-quarterly-sales-of-7-56-billion.html.

In other news, VP Robert A. Michael sold 6,699 shares of the firm’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the transaction, the vice president now directly owns 10,007 shares of the company’s stock, valued at $880,616. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $85.02, for a total value of $705,666.00. Following the transaction, the senior vice president now directly owns 93,099 shares in the company, valued at $7,915,276.98. The disclosure for this sale can be found here. Insiders have sold 33,299 shares of company stock worth $2,952,243 in the last 90 days. Company insiders own 0.23% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Formidable Asset Management LLC grew its stake in shares of AbbVie by 0.3% during the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock valued at $285,000 after buying an additional 10 shares during the last quarter. WealthTrust Axiom LLC grew its stake in shares of AbbVie by 0.3% during the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock valued at $312,000 after buying an additional 15 shares during the last quarter. Abner Herrman & Brock LLC grew its stake in shares of AbbVie by 0.3% during the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock valued at $456,000 after buying an additional 18 shares during the last quarter. Bollard Group LLC grew its stake in shares of AbbVie by 0.5% during the second quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock valued at $273,000 after buying an additional 19 shares during the last quarter. Finally, St. Louis Trust Co grew its stake in shares of AbbVie by 0.7% during the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after buying an additional 23 shares during the last quarter. 68.52% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Get a free copy of the Zacks research report on AbbVie (ABBV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.